ÂÜÀòÂÒÂ×

Kenneth Mills is the Chief Executive Officer, President, and Director of REGENXBIO Inc., a prominent biotechnology company specializing in AAV gene therapy, where Kenneth has been since February 2009. Mills holds additional leadership roles as a Member of the Board of Directors at the Montgomery County Economic Development Corporation and as a Member of the Board of Advisors at The Universities at Shady Grove. Mills co-founded Dimension Therapeutics, focusing on AAV gene therapy products for rare liver diseases, and previously served as Partner at FoxKiser, CFO and Vice President of Business Development at Meso Scale Diagnostics, and Director of Business Development at IGEN International. Kenneth Mills earned a Bachelor of Science in Chemistry from the Massachusetts Institute of Technology.